These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 12499097)
1. Sequential administration of cisplatin-etoposide followed by topotecan in patients with extensive stage small cell lung cancer. A multicenter phase II study. Mavroudis D; Pavlakou G; Blazoyiannakis G; Veslemes M; Apostolopoulou F; Kouroussis Ch; Kakolyris S; Agelaki S; Androulakis N; Vardakis N; Magkanas E; Samonis G; Georgoulias V Lung Cancer; 2003 Jan; 39(1):71-6. PubMed ID: 12499097 [TBL] [Abstract][Full Text] [Related]
2. Cisplatin-etoposide alternating with topotecan in patients with extensive stage small cell lung cancer (SCLC). A multicenter phase II study. Mavroudis D; Veslemes M; Kouroussis Ch; Tzanakis N; Ferdoutsis E; Toumbis M; Ziotopoulos P; Agelidou M; Tselepatiotis E; Kalbakis K; Souglakos J; Magkanas E; Samonis G; Georgoulias V; Lung Cancer; 2002 Oct; 38(1):59-63. PubMed ID: 12367794 [TBL] [Abstract][Full Text] [Related]
3. Sequential versus alternating administration of cisplatin/etoposide and topotecan as first-line treatment in extensive-stage small-cell lung cancer: preliminary results of a Phase III Trial of the Hellenic Oncology Research Group. Ignatiadis M; Mavroudis D; Veslemes M; Boukovinas J; Syrigos K; Agelidou M; Agelidou A; Gerogianni A; Pavlakou G; Tselepatiotis E; Nikolakopoulos J; Georgoulias V Clin Lung Cancer; 2005 Nov; 7(3):183-9. PubMed ID: 16354313 [TBL] [Abstract][Full Text] [Related]
4. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group. Schiller JH; Adak S; Cella D; DeVore RF; Johnson DH J Clin Oncol; 2001 Apr; 19(8):2114-22. PubMed ID: 11304763 [TBL] [Abstract][Full Text] [Related]
5. Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience. Petrioli R; Roviello G; Laera L; Luzzi L; Paladini P; Ghiribelli C; Voltolini L; Martellucci I; Bianco V; Francini E Clin Lung Cancer; 2015 Nov; 16(6):e229-34. PubMed ID: 26072097 [TBL] [Abstract][Full Text] [Related]
6. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma. Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920 [TBL] [Abstract][Full Text] [Related]
7. Sequential dose-dense paclitaxel followed by topotecan in untreated extensive-stage small-cell lung cancer: a Spanish Lung Cancer Group phase II study. Felip E; Rosell R; Domine M; Santomé L; Garrido P; Font A; Carrato A; Terrasa J; Vadell C; Mañe JM; Baselga J; Ann Oncol; 2003 Oct; 14(10):1549-54. PubMed ID: 14504057 [TBL] [Abstract][Full Text] [Related]
8. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. Eckardt JR; von Pawel J; Papai Z; Tomova A; Tzekova V; Crofts TE; Brannon S; Wissel P; Ross G J Clin Oncol; 2006 May; 24(13):2044-51. PubMed ID: 16648504 [TBL] [Abstract][Full Text] [Related]
9. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. Schiller JH; Kim K; Hutson P; DeVore R; Glick J; Stewart J; Johnson D J Clin Oncol; 1996 Aug; 14(8):2345-52. PubMed ID: 8708727 [TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer. Miller AA; Al Omari A; Murry DJ; Case D Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403 [TBL] [Abstract][Full Text] [Related]
11. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer. Mavroudis D; Papadakis E; Veslemes M; Tsiafaki X; Stavrakakis J; Kouroussis C; Kakolyris S; Bania E; Jordanoglou J; Agelidou M; Vlachonicolis J; Georgoulias V; Ann Oncol; 2001 Apr; 12(4):463-70. PubMed ID: 11398877 [TBL] [Abstract][Full Text] [Related]
12. Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: a phase II trial of the North Central Cancer Treatment Group. Jett JR; Hatfield AK; Hillman S; Bauman MD; Mailliard JA; Kugler JW; Morton RF; Marks RS; Levitt R Cancer; 2003 May; 97(10):2498-503. PubMed ID: 12733149 [TBL] [Abstract][Full Text] [Related]
13. A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer. Garst J; Herndon JE; Shafman T; Campagna L; Blackwell S; Padilla K; Bjurstrom T; Andrews C; Maravich-May D; Anderson E; Crawford J Clin Drug Investig; 2006; 26(5):257-66. PubMed ID: 17163259 [TBL] [Abstract][Full Text] [Related]
14. European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer. Ardizzoni A; Manegold C; Debruyne C; Gaafar R; Buchholz E; Smit EF; Lianes P; ten Velde G; Bosquee L; Legrand C; Neumaier C; King K; Clin Cancer Res; 2003 Jan; 9(1):143-50. PubMed ID: 12538462 [TBL] [Abstract][Full Text] [Related]
15. Addition of topotecan to standard cisplatin/etoposide combination in patients with extended stage small cell lung carcinoma. Tas F; Derin D; Guney N; Camlica H; Aydiner A; Topuz E Lung Cancer; 2007 Jul; 57(1):79-83. PubMed ID: 17383768 [TBL] [Abstract][Full Text] [Related]
16. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial. Wolf M; Havemann K; Holle R; Gropp C; Drings P; Hans K; Schroeder M; Heim M; Dommes M; Mende S J Clin Oncol; 1987 Dec; 5(12):1880-9. PubMed ID: 2824710 [TBL] [Abstract][Full Text] [Related]
17. Topotecan and etoposide as first-line therapy for extensive disease small cell lung cancer: a phase II trial of a platinum-free regimen. Reck M; Groth G; Buchholz E; Goetz E; Gatzemeier U; Manegold C Lung Cancer; 2005 Jun; 48(3):409-13. PubMed ID: 15893010 [TBL] [Abstract][Full Text] [Related]
18. Phase III study comparing sequential versus alternate administration of cisplatin-etoposide and topotecan as first-line treatment in small cell lung cancer. Baka S; Agelaki S; Kotsakis A; Veslemes M; Papakotoulas P; Agelidou M; Agelidou A; Tsaroucha E; Pavlakou G; Gerogianni A; Androulakis N; Vamvakas L; Kalbakis K; Mavroudis D; Georgoulias V Anticancer Res; 2010 Jul; 30(7):3031-8. PubMed ID: 20683051 [TBL] [Abstract][Full Text] [Related]
19. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B. Miller AA; Herndon JE; Hollis DR; Ellerton J; Langleben A; Richards F; Green MR J Clin Oncol; 1995 Aug; 13(8):1871-9. PubMed ID: 7636529 [TBL] [Abstract][Full Text] [Related]
20. Sequencing topotecan and etoposide plus cisplatin to overcome topoisomerase I and II resistance: a pharmacodynamically based Phase I trial. Aisner J; Musanti R; Beers S; Smith S; Locsin S; Rubin EH Clin Cancer Res; 2003 Jul; 9(7):2504-9. PubMed ID: 12855624 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]